Roxanne K. Branford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roxanne K. Branford has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Adriana P. Gonzalez Frontera
Internal Medicine, University of Medicine and Health Sciences, Basseterre, KNA
1 shared publicationLuis Hernandez Lopez
Internal Medicine, Ross University School of Medicine, St. Michael, BRB
1 shared publicationMargaret Ledea
Internal Medicine, Cleveland Clinic Florida, Weston, USA
1 shared publication
Latest Publications
- Open Access
- 21 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e95038
Pembrolizumab-Induced Capillary Leak Syndrome: A Rare but Life-Threatening Immune-Related Adverse Event
Capillary leak syndrome (CLS) is an exceptionally rare and potentially life-threatening adverse event characterized by the abrupt shift of intravascular fluid into the extravascular compartment, leading to profound hypotension, edema, and potential multi-organ dysfunction. This condition has been associated with immune checkpoint inhibitors (ICIs) such as pembrolizumab. We present the case of a 67-year-old woman with a history of squamous cell lung carcinoma who underwent four cycles of pembrolizumab and presented multiple times with progressive shortness of breath, anasarca, and dyspnea on exertion. Clinical evaluation ruled out common causes of respiratory compromise and fluid overload, prompting consideration of immune-mediated pathology. Diagnostic studies and clinical evolution supported a diagnosis of CLS, underscoring the importance of early recognition and intervention. This case highlights CLS as a severe but treatable toxicity of pembrolizumab, emphasizing that timely detection and appropriate supportive care are essential for favorable clinical outcomes.
- 21 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e95038
Open AccessPembrolizumab-Induced Capillary Leak Syndrome: A Rare but Life-Threatening Immune-Related Adverse Event
Capillary leak syndrome (CLS) is an exceptionally rare and potentially life-threatening adverse event characterized by the abrupt shift of intravascular fluid into the extravascular compartment, leading to profound hypotension, edema, and potential multi-organ dysfunction. This condition has been associated with immune checkpoint inhibitors (ICIs) such as pembrolizumab. We present the case of a 67-year-old woman with a history of squamous cell lung carcinoma who underwent four cycles of pembrolizumab and presented multiple times with progressive shortness of breath, anasarca, and dyspnea on exertion. Clinical evaluation ruled out common causes of respiratory compromise and fluid overload, prompting consideration of immune-mediated pathology. Diagnostic studies and clinical evolution supported a diagnosis of CLS, underscoring the importance of early recognition and intervention. This case highlights CLS as a severe but treatable toxicity of pembrolizumab, emphasizing that timely detection and appropriate supportive care are essential for favorable clinical outcomes.